Drug Profile
Insulin glargine biosimilar - Biocon
Alternative Names: Basalog; bGlargine; GALACTUS; Glaricon; insulin glargine-yfgn injection - Biocon; MYL-1501D; SemgleeLatest Information Update: 03 Aug 2023
Price :
$50
*
At a glance
- Originator Biocon
- Developer Abdi Ibrahim Remede Pharma; Biocon; PiSA Farmaceutica; Viatris Inc
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 03 Aug 2023 Launched for Type 1 diabetes mellitus (In adolescents, In children, In adults) in Singapore, Spain, Portugal, Netherlands, Denmark, Germany, Poland (SC) (Biocon website, August 2023)
- 03 Aug 2023 Launched for Type 1 diabetes mellitus in Mexico, Canada (SC) (Biocon website, August 2023)
- 03 Aug 2023 Launched for Type 2 diabetes mellitus (In adolescents, In children, In adults) in Singapore, Spain, Portugal, Netherlands, Denmark, Germany, Poland, Australia (SC) (Biocon website, August 2023)